{"database": "lobbying", "table": "lobbying_activities", "rows": [[629032, "f6d2109f-ae47-4f6c-96cd-1845c066c10c", "Q2", "TIMMONS AND COMPANY, INC.", 38164, "TEVA PHARMACEUTICALS USA INC", 2008, "second_quarter", "PHA", "S. 28 - To amend title XVIII of the Social Security Act to require the use of generic drugs under the Medicare part D prescription drug program when available unless the brand name drug is determined to be medically necessary.\nS. 1505 - Affordable Biologics for Consumers Act. S. 1695 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, to promote innovation in the life sciences, and for other purposes.\nS. 242 - Pharmaceutical Market Access and Drug Safety Act of 2007.\nS. 251 - Pharmaceutical Market Access Act of 2007.\nS. 1082 - Prescription Drug User Fee Amendments of 2007.\nH.R. 2900 - Food and Drug Administration Amendments Act of 2007.\nH.R. 1956 - Patient Protection and Innovative Biologic Medicines Act.\nH.R. 1038 - Access to Life-Saving Medicine Act.\nH.R. 5629 - Pathway for Biosimilars Act\nH.R. 3610 - Food and Drug Import Safety Act of 2007 \nH.R. 3624 - Consumer Food Safety Act of 2007", "HOUSE OF REPRESENTATIVES,SENATE", 100000, null, 0, 0, "2008-07-15T16:19:28-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["629032"], "units": {}, "query_ms": 7.48563400702551, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}